Good evening :)
$
₹
Grifols SA ADR

Grifols SA ADR

GRFS

NASDAQ
Asset Logo

Grifols SA ADR

GRFS

NASDAQ
$7.781.20% (-0.09)
$
₹
$7.781.20% (-0.09)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Drug Manufacturers - General

Mid Cap

With a market cap of $5.3B the stock is ranked 1437

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

10.03
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.81
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.78
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.22
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

6.09%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

3.65%

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 2 analysts' reports

Buy
1 analyst
Hold
1 analyst
Sell
0 analyst

Analysts expect a +39.29% price upside over the next year

Current Price$7.78
Target Price$10.86

Company Profile

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
—
—
P/E Ratio
73.51
73.51
—
—
1Y Return
23.04%
23.04%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
—
—
P/E Ratio
27.25
27.25
—
—
1Y Return
57.21%
57.21%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
—
—
P/E Ratio
—
—
—
—
1Y Return
34.82%
34.82%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
—
—
P/E Ratio
31.85
31.85
—
—
1Y Return
37.58%
37.58%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
—
—
P/E Ratio
20.36
20.36
—
—
1Y Return
46.1%
46.1%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - General

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Grifols SA ADR 10.030.810.22
AbbVie Inc73.5150.450.36
Amgen Inc27.2520.262.10

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

1.8
0.1
1.9
0
1.7
0
1.8
0.1
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue1.621.811.791.971.781.891.861.961.721.87
Net Income0.020.010.050.060.050.110.120.090.070.15
Net Profit Margin1.31%0.81%2.88%3.49%3.34%6.19%6.80%4.95%4.29%8.21%
See CostsAll values in $ Billion

Frequently asked questions

Frequently asked questions

  1. Grifols SA ADR (GRFS) share price today is $7.78 as of September 5, 2026 at 1:30 AM IST. The stock touched a day high of $7.84 and a day low of $7.78.

  2. Grifols SA ADR stock trades on NASDAQ under the ticker symbol GRFS.

  3. Grifols SA ADR's market capitalization is $5.32B as of September 5, 2026 at 1:30 AM IST.

  4. Grifols SA ADR's price-to-earnings (P/E) ratio is 10.03 as of September 4, 2026.

  5. Grifols SA ADR's price-to-book (P/B) ratio is 0.81 as of September 4, 2026.

  6. Yes, Grifols SA ADR pays a dividend, with a current dividend yield of 3.65%.

  7. Yes, You can buy Grifols SA ADR shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Grifols SA ADR shares in three steps: 1. Search Grifols SA ADR on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Grifols SA ADR trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Grifols SA ADR (GRFS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.2845 shares at the current price of $7.78.

Loading...